CERS
Price
$1.96
Change
-$0.07 (-3.45%)
Updated
May 16, 6:59 PM EST
77 days until earnings call
STAA
Price
$42.62
Change
-$0.52 (-1.21%)
Updated
May 16, 6:59 PM EST
76 days until earnings call
Ad is loading...

CERS vs STAA

Header iconCERS vs STAA Comparison
Open Charts CERS vs STAABanner chart's image
Cerus
Price$1.96
Change-$0.07 (-3.45%)
Volume$483.47K
CapitalizationN/A
STAAR Surgical
Price$42.62
Change-$0.52 (-1.21%)
Volume$130.89K
CapitalizationN/A
View a ticker or compare two or three
CERS vs STAA Comparison Chart

Loading...

CERSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
STAADaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
CERS vs. STAA commentary
May 17, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a Hold and STAA is a StrongSell.

COMPARISON
Comparison
May 17, 2024
Stock price -- (CERS: $2.03 vs. STAA: $43.14)
Brand notoriety: CERS and STAA are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CERS: 68% vs. STAA: 46%
Market capitalization -- CERS: $342.62M vs. STAA: $1.91B
CERS [@Medical Specialties] is valued at $342.62M. STAA’s [@Medical Specialties] market capitalization is $1.91B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.47B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CERS’s FA Score shows that 0 FA rating(s) are green whileSTAA’s FA Score has 1 green FA rating(s).

  • CERS’s FA Score: 0 green, 5 red.
  • STAA’s FA Score: 1 green, 4 red.
According to our system of comparison, STAA is a better buy in the long-term than CERS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CERS’s TA Score shows that 5 TA indicator(s) are bullish while STAA’s TA Score has 4 bullish TA indicator(s).

  • CERS’s TA Score: 5 bullish, 4 bearish.
  • STAA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, CERS is a better buy in the short-term than STAA.

Price Growth

CERS (@Medical Specialties) experienced а +7.98% price change this week, while STAA (@Medical Specialties) price change was +5.17% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +2.02%. For the same industry, the average monthly price growth was +4.43%, and the average quarterly price growth was +17.15%.

Reported Earning Dates

CERS is expected to report earnings on Aug 01, 2024.

STAA is expected to report earnings on Jul 31, 2024.

Industries' Descriptions

@Medical Specialties (+2.02% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
A.I.dvisor published
a Summary for CERS with price predictions.
OPEN
A.I.dvisor published
a Summary for STAA with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
STAA($1.91B) has a higher market cap than CERS($343M). STAA YTD gains are higher at: 38.225 vs. CERS (-6.019). STAA has higher annual earnings (EBITDA): 33.2M vs. CERS (-26.34M). STAA has more cash in the bank: 221M vs. CERS (65.9M). STAA has less debt than CERS: STAA (35.8M) vs CERS (96M). STAA has higher revenues than CERS: STAA (322M) vs CERS (156M).
CERSSTAACERS / STAA
Capitalization343M1.91B18%
EBITDA-26.34M33.2M-79%
Gain YTD-6.01938.225-16%
P/E RatioN/A90.79-
Revenue156M322M48%
Total Cash65.9M221M30%
Total Debt96M35.8M268%
FUNDAMENTALS RATINGS
CERS vs STAA: Fundamental Ratings
CERS
STAA
OUTLOOK RATING
1..100
3668
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
88
Overvalued
PROFIT vs RISK RATING
1..100
10086
SMR RATING
1..100
9782
PRICE GROWTH RATING
1..100
4950
P/E GROWTH RATING
1..100
10027
SEASONALITY SCORE
1..100
5095

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CERS's Valuation (52) in the Medical Specialties industry is somewhat better than the same rating for STAA (88). This means that CERS’s stock grew somewhat faster than STAA’s over the last 12 months.

STAA's Profit vs Risk Rating (86) in the Medical Specialties industry is in the same range as CERS (100). This means that STAA’s stock grew similarly to CERS’s over the last 12 months.

STAA's SMR Rating (82) in the Medical Specialties industry is in the same range as CERS (97). This means that STAA’s stock grew similarly to CERS’s over the last 12 months.

CERS's Price Growth Rating (49) in the Medical Specialties industry is in the same range as STAA (50). This means that CERS’s stock grew similarly to STAA’s over the last 12 months.

STAA's P/E Growth Rating (27) in the Medical Specialties industry is significantly better than the same rating for CERS (100). This means that STAA’s stock grew significantly faster than CERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CERSSTAA
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
82%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 2 days ago
70%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bullish Trend 1 day ago
72%
Bearish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
79%
Declines
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 16 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
CERSDaily Signal changed days agoGain/Loss if shorted
 
Show more...
STAADaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FPURX25.580.29
+1.15%
Fidelity Puritan
BRKSX13.850.10
+0.73%
MFS Blended Research Em Mkts Eq R2
IASAX10.470.04
+0.38%
VY® American Century Sm-Mid Cp Val A
KDHAX55.550.04
+0.07%
DWS CROCI Equity Dividend A
GEMUX23.30N/A
N/A
Goldman Sachs Emerging Markets Eq R6

CERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CERS has been loosely correlated with VCYT. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERS
1D Price
Change %
CERS100%
-0.49%
VCYT - CERS
50%
Loosely correlated
+2.30%
KIDS - CERS
44%
Loosely correlated
+0.16%
TWST - CERS
43%
Loosely correlated
+0.48%
CDNA - CERS
43%
Loosely correlated
-3.02%
FLGT - CERS
43%
Loosely correlated
+1.12%
More

STAA and

Correlation & Price change

A.I.dvisor indicates that over the last year, STAA has been loosely correlated with XRAY. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if STAA jumps, then XRAY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To STAA
1D Price
Change %
STAA100%
-1.17%
XRAY - STAA
53%
Loosely correlated
+0.50%
NVST - STAA
48%
Loosely correlated
-1.62%
WST - STAA
44%
Loosely correlated
-0.84%
VCYT - STAA
40%
Loosely correlated
+2.30%
INSP - STAA
37%
Loosely correlated
+0.73%
More